OncoMatch

OncoMatch/Clinical Trials/NCT06010888

Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC

Is NCT06010888 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Fruquintinib+mFOLFOX6/FOLFIRI for colorectal cancer.

Phase 2RecruitingFudan UniversityNCT06010888Data as of May 2026

Treatment: Fruquintinib+mFOLFOX6/FOLFIRIThe goal of this clinical trial is to learn about the efficacy and safety of Fruquintinib with mFOLFOX6/FOLFIRI in patients with mCRC. The main question it aims to answer is: The conversion surgery rate of the therapy mentioned above. The ORR, R0 surgery rate, DCR, PFS, OS, and safety will be evaluated.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Biomarker criteria

Required: KRAS mutation status determined

RAS/BRAF mutation status ... should be determined before enrollment.

Required: NRAS mutation status determined

RAS/BRAF mutation status ... should be determined before enrollment.

Required: BRAF mutation status determined

RAS/BRAF mutation status ... should be determined before enrollment.

Required: UGT1A1 *28/*6 gene polymorphism typing determined

UGT1A1*28/*6 gene polymorphism typing should be determined before enrollment.

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: systemic anti-tumor therapy

Exception: neoadjuvant/adjuvant therapy allowed if >6 months since last chemotherapy to recurrence or progression

Have not received systematic anti-tumor therapy before; Patients who have received neoadjuvant/adjuvant therapy may be screened from the time of last chemotherapy to recurrence or progression more than 6 months.

Lab requirements

Blood counts

ANC ≥1.5×10^9/L; Platelet ≥100×10^9/L; Hemoglobin ≥9g/dL; Serum albumin ≥2.5g/dL

Kidney function

Serum creatinine ≤1.5 × ULN or creatinine clearance > 60 mL/min (Cockcroft-Gault)

Liver function

Total bilirubin ≤1.5 × ULN; ALT and AST≤2.5 × ULN, if there is liver metastasis, ALT and AST≤5 × ULN

The function of vital organs meets the following requirements ... (see full text for details)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify